Pharmaceutical & Biopharmaceutical Market was Agilent Technologies’s largest region in fiscal 2025, bringing in $2.51B of $6.95B (36%).
| End Markets | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Pharmaceutical & Biopharmaceutical Market | $2.52B | $2.43B | $2.24B | $2.51B | |||
| Chemical & Advanced Materials Market | $1.52B | $1.54B | $1.50B | $1.56B | |||
| Chemical & Energy Market | — | — | — | — | |||
| Diagnostics & Clinical Market | $963.00M | $966.00M | $964.00M | $1.03B | |||
| Environmental & Forensics Market | $656.00M | $662.00M | $650.00M | $674.00M | |||
| Food Market | $617.00M | $628.00M | $592.00M | $637.00M | |||
| Academia & Government Market | $576.00M | $601.00M | $567.00M | $540.00M | |||
| Total | $6.85B | $6.83B | $6.51B | $6.95B |
Agilent Technologies brought in $6.95B from its six regions in fiscal 2025, the year ended October 31, 2025. That was up 6.7% from $6.51B in fiscal 2024. Pharmaceutical & Biopharmaceutical Market was the largest at $2.51B (36.1%), ahead of Chemical & Advanced Materials Market at $1.56B (22.5%) and Diagnostics & Clinical Market at $1.03B (14.8%). The other three regions brought in $1.85B combined.
Compared with fiscal 2024, Pharmaceutical & Biopharmaceutical Market grew fastest, up 11.8% to $2.51B, while Academia & Government Market fell the most, down 4.8% to $540.00M. From fiscal 2022 to 2025, combined revenue from these regions grew from $6.85B to $6.95B, a compound annual growth rate of 0.5%. Pharmaceutical & Biopharmaceutical Market's share of the total fell from 36.7% to 36.1%.
Life Sciences & Diagnostics Markets was Agilent Technologies’s largest segment in fiscal 2025, bringing in $1.34B of $3.05B (44%).
| Business Segments | FY 2009 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Life Sciences & Applied Markets | $1.68B | — | — | — | ||||||||||
| Electronic Measurement | — | — | — | — | ||||||||||
| Life Sciences & Diagnostics Markets | — | $1.33B | $1.16B | $1.34B | ||||||||||
| Life Sciences | — | — | — | — | ||||||||||
| Agilent Crosslab | $567.00M | $1.00B | $1.05B | $1.10B | ||||||||||
| Diagnostics & Genomics | $1.01B | — | — | — | ||||||||||
| Chemical Analysis | — | — | — | — | ||||||||||
| Applied Markets | — | $677.00M | $623.00M | $614.00M | ||||||||||
| Total | $3.25B | $3.01B | $2.83B | $3.05B |
Agilent Technologies brought in $3.05B from its three segments in fiscal 2025, the year ended October 31, 2025. That is less than the $6.95B it reports by end markets, so these segments do not cover all of its revenue. Life Sciences & Diagnostics Markets was the largest at $1.34B (43.9%), ahead of Agilent Crosslab at $1.10B (35.9%) and Applied Markets at $614.00M (20.2%).
Compared with fiscal 2024, Life Sciences & Diagnostics Markets grew fastest, up 15.6% to $1.34B, while Applied Markets fell the most, down 1.4% to $614.00M.
Agilent Technologies began breaking out Life Sciences & Diagnostics Markets in fiscal 2023 and Applied Markets in fiscal 2023. Agilent Technologies stopped reporting Life Sciences & Applied Markets ($1.68B in fiscal 2022) and Diagnostics & Genomics ($1.01B in fiscal 2022) as separate segments.
Products was Agilent Technologies’s largest product and service line in fiscal 2025, bringing in $4.94B of $6.95B (71%).
| Product and Service | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Products | $5.19B | $5.05B | $4.67B | $4.94B | |||||||||
| Instrumentation | — | — | — | — | |||||||||
| Services & Other | $1.66B | $1.78B | $1.84B | $2.00B | |||||||||
| Analytical Lab Services | — | — | — | — | |||||||||
| Diagnostics & Genomics Solutions | — | — | — | — | |||||||||
| Analytical Lab Consumables | — | — | — | — | |||||||||
| Informatics & Other | — | — | — | — | |||||||||
| Total | $6.85B | $6.83B | $6.51B | $6.95B |
Agilent Technologies brought in $6.95B from its two product and service lines in fiscal 2025, the year ended October 31, 2025. That was up 6.7% from $6.51B in fiscal 2024. Products was the largest at $4.94B (71.2%), ahead of Services & Other at $2.00B (28.8%).
Compared with fiscal 2024, Services & Other grew 9.0% to $2.00B and Products grew 5.8% to $4.94B. From fiscal 2022 to 2025, combined revenue from these lines grew from $6.85B to $6.95B, a compound annual growth rate of 0.5%. Products' share of the total fell from 75.7% to 71.2%.
Agilent Technologies (A) reports its revenue by end markets, by business segments and by product and service. In fiscal 2025, Pharmaceutical & Biopharmaceutical Market was its largest region, bringing in $2.51B (36.1% of the total), followed by Chemical & Advanced Materials Market at $1.56B (22.5%).
Pharmaceutical & Biopharmaceutical Market was Agilent Technologies' largest region in fiscal 2025, bringing in $2.51B, or 36.1% of the $6.95B total across its six regions.
Life Sciences & Diagnostics Markets was Agilent Technologies' largest segment in fiscal 2025, bringing in $1.34B, or 43.9% of the $3.05B total across its three segments.
Products was Agilent Technologies' largest product and service line in fiscal 2025, bringing in $4.94B, or 71.2% of the $6.95B total across its two product and service lines.
Among Agilent Technologies' regions that make up at least 2% of revenue, Pharmaceutical & Biopharmaceutical Market grew fastest in fiscal 2025, up 11.8% from $2.24B to $2.51B.
Every figure comes from Agilent Technologies' annual financial filings, as reported. Each line keeps the name Agilent Technologies gives it, and years follow its fiscal calendar.
Agilent Technologies' revenue by end markets goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.